NAD+ Therapy
SubQ · IM · IV Infusion

Purpose of Therapy

Nicotinamide Adenine Dinucleotide (NAD+) therapy is an elective wellness and performance-support treatment intended to support mitochondrial function, cellular energy production, neurological performance, and recovery processes. NAD+ is a naturally occurring coenzyme found in all living cells.

This consent covers two delivery models:

The route, dose, and frequency are determined by the provider based on clinical judgment, patient goals, tolerance, and safety considerations. I understand that:

• Supplemental NAD+ therapy is not FDA-approved to diagnose, treat, cure, or prevent any disease
• NAD+ therapy is considered off-label and elective, provided for wellness and optimization purposes only
• NAD+ used in this practice is sourced from licensed 503A or 503B compounding pharmacies and is a non-FDA-approved compounded product

State Licensure & Scope

Navara Health provides NAD+ therapy only where the treating provider is licensed and where the therapy is lawful. I acknowledge:

• In-clinic IV NAD+ infusions are provided only at the Dallas, Texas office. Navara Health does not provide mobile or in-home NAD+ IV services.
• Self-administered SubQ or IM NAD+ is prescribed and shipped only to patients physically located in: Texas, Colorado, Connecticut, Florida, Iowa, Oklahoma, Vermont, Virginia, and Washington.
• NAD+ is not a controlled substance. The Texas-only restriction that applies to controlled substances does not apply to NAD+.
• I will inform Navara Health promptly if I relocate or am temporarily located outside my listed state of residence.

Voluntary Nature of Treatment & Alternatives

NAD+ therapy is elective and voluntary. Reasonable alternatives include, but are not limited to:

• No treatment
• Oral NAD+ precursors (such as nicotinamide riboside or nicotinamide mononucleotide)
• Lifestyle interventions: sleep optimization, exercise, caloric restriction, fasting protocols
• Dietary modification and B-vitamin supplementation
• Ongoing care with a primary care provider or specialist for any underlying condition

I may decline or discontinue NAD+ therapy at any time without affecting other aspects of my care with Navara Health.

Typical Dosing & Treatment Guidelines

I understand that:

• Dosing and frequency may be adjusted or discontinued at any time at the provider's discretion
• Adequate hydration before and after treatment is recommended
• Higher doses and faster infusion rates may increase side effects
• Infusion rate may be slowed, paused, or discontinued during treatment to manage side effects or ensure safety

Potential Benefits

Reported benefits in clinical literature and patient experience may include, but are not limited to:

• Increased physical and mental energy
• Improved cognitive clarity, focus, or memory
• Enhanced mood or stress resilience
• Support for cellular repair and longevity pathways
• Neuroprotective or neurological support
• Improved recovery following physical exertion, illness, or stress

Potential Risks & Side Effects

SubQ or IM Injection Risks

IV Infusion Risks

I understand that unforeseeable complications may occur, even with appropriate screening, dosing, and technique. Infusion rate may need to be slowed, paused, or discontinued at the provider's discretion to reduce side effects or ensure safety.

Contraindications & Precautions

NAD+ therapy may not be appropriate, or may require additional caution, if I have or disclose a history of:

• Active infection, fever, or acute illness
• Uncontrolled hypertension or cardiovascular instability
• Significant anxiety disorders or sensitivity to stimulatory agents
• History of severe or frequent migraines
• Pregnancy, possible pregnancy, or breastfeeding
• Known allergy or hypersensitivity to NAD+ or formulation components (including preservatives or excipients)
• Active cancer treatment (NAD+ effects on tumor metabolism are not fully established)
• Significant hepatic or renal impairment
• History of severe vasovagal reactions or fainting during medical procedures

Self-Administration Responsibilities (Model B)

For self-administered SubQ or IM NAD+, I acknowledge and agree that:

• I will receive written and/or video instructions on technique, reconstitution (if applicable), site rotation, dose preparation, storage, and sharps disposal
• I will not administer my first dose until I have confirmed I understand the instructions
• I will start at the lowest prescribed dose and titrate up only as directed
• I will store NAD+ as directed by the prescribing provider and dispensing pharmacy (typically refrigerated, protected from light)
• I will not share, sell, transfer, or allow another person to use any NAD+ prescribed to me
• I will use a proper sharps container and dispose of needles in accordance with state and local regulations
• I will keep all required follow-up appointments
• I will contact Navara Health before the next dose if I experience an unexpected reaction, technique concern, or significant side effect

When to Stop and Call Navara Health

I will stop self-administration and contact Navara Health immediately if I experience:

• Significant chest pressure, palpitations, or chest pain
• Severe headache, vision changes, or one-sided weakness
• Hives, swelling of face/lips/tongue, or any sign of allergic reaction
• Persistent injection-site infection (worsening redness, warmth, drainage, fever)
• Severe panic, agitation, or worsening mood symptoms
• Any reaction I am uncertain about

Limitations of Therapy

I understand and acknowledge that:

• NAD+ therapy is not medical treatment for disease
• It does not replace primary care, specialty care, mental health care, or emergency services
• Results vary widely and are not guaranteed
• Ongoing or repeated treatments may be required for perceived benefit, and benefits may diminish if therapy is discontinued
• NAD+ is not a substitute for evidence-based treatment of any diagnosed condition

Financial Disclosure

I understand and agree that:

• NAD+ therapy is elective and not covered by insurance
• Navara Health is a cash-pay practice and does not bill, verify, or submit claims to insurance, Medicare, or Medicaid for NAD+ therapy
• Payment is due at the time of service or at the time of medication ordering
• No refunds are issued once: (a) medication is prepared, opened, or shipped, (b) an injection is administered, or (c) an IV infusion has started
• Additional services, supplies, or treatments recommended may incur separate charges, disclosed in advance where possible
• Pricing, refund policies, and shipping practices for self-administered NAD+ are governed by the dispensing pharmacy and are outside Navara Health's control

Communication & HIPAA Authorization

I authorize Navara Health to communicate with me regarding scheduling, infusion coordination, refills, monitoring, and follow-up through:

• The secure HIPAA-compliant patient portal
• Email to the address I have provided
• SMS / text message to the mobile number I have provided
• Telephone calls to the number I have provided

I understand that email and SMS are not fully secure channels. I may revoke authorization for any specific channel in writing to contact@navarahealthtx.com, except where required for legally mandated notices.

Assumption of Risk & Release of Liability

I voluntarily assume all known and unknown risks associated with NAD+ therapy. To the fullest extent permitted by law, I agree to release, indemnify, and hold harmless Navara Health, PLLC, Jessica Boggs APRN, the medical director, and all affiliated providers, nurses, staff, contractors, and agents from liability for:

• Adverse reactions
• Side effects
• Unexpected outcomes
• Lack of benefit
• Worsening of symptoms
• Treatment failure or complications

This release does not apply to cases of gross negligence or willful misconduct, and does not waive any right that cannot lawfully be waived under the laws of my state of residence.

Dispute Resolution & Binding Arbitration

Any dispute, controversy, or claim arising out of or relating to this Consent, the services provided, or the practitioner-patient relationship — including any claim of medical malpractice, billing dispute, or breach of contract — shall first be addressed by good-faith negotiation between the parties.

If the matter cannot be resolved through negotiation within thirty (30) days, the parties agree to submit the dispute to binding arbitration administered by a recognized arbitration body (such as the American Arbitration Association) under its applicable rules, with the arbitration to take place in Dallas County, Texas, unless otherwise required by the laws of the patient's state of residence.

The parties acknowledge that by agreeing to arbitration, they are waiving the right to a jury trial. This provision does not waive any right that cannot lawfully be waived under the patient's state law. Either party retains the right to seek injunctive or equitable relief in court where appropriate.

Governing Law & Severability

This Consent shall be governed by and construed under the laws of the State of Texas, except where the laws of the patient's state of residence require otherwise. If any provision is found unenforceable, the remaining provisions shall remain in full force and effect.

Emergency & Adverse Event Reporting

During in-clinic infusion, I will immediately notify clinical staff if I experience pain, discomfort, dizziness, nausea, chest symptoms, or any sign of allergic reaction. For non-emergent adverse events at home, I will report through the patient portal or by calling 469-653-3124. Suspected drug-related adverse events may also be reported to the FDA MedWatch program at 1-800-FDA-1088 or fda.gov/medwatch.